Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Decrease in Short Interest

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 472,700 shares, a decrease of 13.7% from the January 15th total of 547,500 shares. Based on an average daily volume of 349,100 shares, the days-to-cover ratio is currently 1.4 days. Currently, 2.3% of the shares of the stock are short sold.

Aadi Bioscience Price Performance

Shares of NASDAQ AADI opened at $2.73 on Wednesday. The stock has a market cap of $67.29 million, a PE ratio of -1.20 and a beta of 0.65. Aadi Bioscience has a 1 year low of $1.21 and a 1 year high of $3.81. The firm has a fifty day moving average price of $2.85 and a 200-day moving average price of $2.20.

Aadi Bioscience (NASDAQ:AADI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.46). The business had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.55 million. Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. During the same quarter in the prior year, the business posted ($0.60) EPS. On average, research analysts expect that Aadi Bioscience will post -2.04 EPS for the current year.

Institutional Investors Weigh In On Aadi Bioscience

A number of institutional investors have recently added to or reduced their stakes in AADI. XTX Topco Ltd purchased a new position in shares of Aadi Bioscience in the third quarter valued at $32,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Aadi Bioscience in the 2nd quarter worth $37,000. Peapod Lane Capital LLC purchased a new position in shares of Aadi Bioscience in the 4th quarter worth $1,397,000. Finally, BML Capital Management LLC bought a new position in shares of Aadi Bioscience in the 3rd quarter valued at about $4,120,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.